Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 82Lymphoid 11Sarcoma 7Other hematologic neoplasm 4Thoracic 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 2Uveal Melanoma 1Brain Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lomustine × Dermatologic × Clear all
NCT00527657 2018-11-14

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

M.D. Anderson Cancer Center

Phase 1 Completed
17 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡